RxDoctor Payments Data

Raquel Diaz-Guerrero, MD

Psychiatry · Sharon, PANPI 1720371032

Payments from drug & device makers

$2,518in general payments, 2019–2025

Across 173 payments — averaging $14.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$388
  • Otsuka America Pharmaceutical, Inc.$344
  • Sunovion Pharmaceuticals Inc.$318
  • Lundbeck LLC$217
  • Takeda Pharmaceuticals U.S.A., Inc.$187
  • Teva Pharmaceuticals USA, Inc.$156
  • plus $907 from 15 others

What the payments were for

  • Food & beverage$2,510100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,518 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$6,528
Medicare patients
18
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Chlorpromazine Hcl23$5,523
VyvanseLisdexamfetamine Dimesylate11$3,991
Paliperidone ErPaliperidone19$3,454
Divalproex Sodium ErDivalproex Sodium81$2,685
Lamotrigine99$2,025
Duloxetine Hcl118$1,512
Divalproex Sodium38$1,433
Buspirone Hcl67$1,400
Methylphenidate ErMethylphenidate Hcl20$1,359
Aripiprazole58$1,354
Quetiapine Fumarate86$1,255
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$983
Risperidone106$961
Clonazepam109$848
Quetiapine Fumarate ErQuetiapine Fumarate17$663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$187$3,99111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Sharon

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →